Cytomos

Executive Summary

Cytomos is a UK-based biotechnology company founded in 2019 that has developed the AuraCyt® platform, a label-free, real-time single-cell analysis technology. The platform addresses critical bottlenecks in bioprocessing by enabling rapid characterization of cell health, productivity, and quality without the need for dyes or labels. This capability is particularly valuable in cell line development, viral vector production, and cell therapy manufacturing, where traditional methods are often time-consuming and disruptive to cells. By providing real-time, actionable data, AuraCyt® aims to improve process efficiency, reduce costs, and accelerate development timelines for biologics and cell therapies. The company's technology differentiates itself through its non-invasive, high-throughput approach, which preserves cell viability while delivering deep phenotypic insights. With growing demand for cell and gene therapies, Cytomos is well-positioned to capture market share in the analytical tools segment. Although the company is still in its early stages with limited public financials, its innovative platform has the potential to become a standard tool across biomanufacturing. Near-term focus on commercial partnerships and regulatory validation will be key to realizing its value proposition.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round to Scale Commercial Operations70% success
• H2 2026Strategic Partnership with a Cell Therapy Developer60% success
• Q4 2026Commercial Launch of AuraCyt Platform for Viral Vector QC50% success